1. Erdheim-Chester disease: atypical presentation of a rare disease.
- Author
-
Calandra CR, Bustos A, Falcon F, and Arakaki N
- Subjects
- Adult, DNA Mutational Analysis, Diplopia etiology, Erdheim-Chester Disease physiopathology, Erdheim-Chester Disease therapy, Humans, Male, Neuroimaging, Rare Diseases, Recombinant Proteins therapeutic use, Treatment Outcome, Trismus etiology, Antiviral Agents therapeutic use, Cytoreduction Surgical Procedures methods, Erdheim-Chester Disease diagnosis, Histiocytes pathology, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Tomography, X-Ray Computed
- Abstract
We report the clinical case of an adult patient referred to our hospital because of trismus due to a tumour in the right infratemporal and pterygomaxillary fossa. He referred hyporexia, weight loss and right trigeminal neuralgia. On physical examination, he had trismus and diplopia. On neuroimaging, the tumour invaded the central nervous system affecting the right temporal lobe and orbit, and the sellar region. Tumour biopsy revealed foamy histiocytes and isolated giant multinuclear cells immunoreactive to CD68 and negative to CD1a and S100. A diagnosis of Erdheim-Chester disease was made. Non-evidence of large bone involvement was found in neither plain radiographs nor Technetium 99 m bone scintigraphy. BRAFV600E mutation analysis was negative. Because of raised intracranial pressure, a debulking surgery of the intracranial histiocytic process was performed. The patient improved his symptoms and remains clinically stable after 12 months of treatment with pegylated interferon-α-2a 180 µg/weekly., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2017
- Full Text
- View/download PDF